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Pulmonary arterial hypertension (PAH) is an incurable disorder clinically characterised by a sustained elevation of mean arterial
pressure in the absence of systemic involvement. As the adult circulation is a low pressure, low resistance system, PAH represents
a reversal to a foetal state. e small pulmonary arteries of patients exhibit luminal occlusion resultant from the uncontrolled
growth of endothelial and smooth muscle cells. is vascular remodelling is comprised of hallmark defects, most notably the
plexiform lesion. PAH may be familial in nature but the majority of patients present with spontaneous disease or PAH associated
with other complications. In this paper, the molecular genetic basis of the disorder is discussed in detail ranging from the original
identi�cation of the major genetic contributant to PAH andmoving on to current next-generation technologies that have led to the
rapid identi�cation of additional genetic risk factors. e impact of identi�ed mutations on the cell is examined, particularly, the
determination of pathways disrupted in disease and critical to pulmonary vascular maintenance. Finally, the application of research
in this area to the design and development of novel treatment options for patients is addressed along with the future directions PAH
research is progressing towards.
1. Pulmonary Vascular Development
ree distinct models have been put forward in an attempt
to shed light on the processes underlying the development of
the pulmonary vascular bed and, in particular, the respective
roles played by the key morphological events of vascu-
logenesis and angiogenesis. Vasculogenesis is de�ned by
recruitment and diﬀerentiation of the endothelial progenitor
cells into mature endothelial cells which proliferate, migrate,
diﬀerentiate, and organise into a vascular plexus that forms
the foundation for the early vascular system. Angiogenesis
is the process of branching growth from existing vessels.
Favouring angiogenesis as the predominant mechanism in
pulmonary vascular development, Parera et al. suggest that
expansion of the lung bud is resultant upon the formation of
new capillary structures from previously established vessels
[1]. By contrast, Hall et al. support vasculogenesis as the
central process driving the generation of arteries and veins
from the central vascular plexus [2]. Finally, deMello and
Reid implicate both processes in vascular development,
positing the theory that the early events involve the diﬀer-
entiation of mesenchymal cells to endothelial populations
that is succeeded by angiogenic mechanisms impacting on
endothelial cells derived from preexistent vessels [3].
e development of the pulmonary vascular system and
circulation depends on an array of genetic factors working
in a tightly regulated spatiotemporal fashion. ese elements
include transcription factors and cytokines amongst others.
Among the key factors known to regulate vessel formation are
the vascular endothelial growth factor (VEGF), transforming
growth factor beta (TGF-𝛽𝛽) family members, and angiopoi-
etins along with several growth factor receptors [4]. Of
these VEGF is intrinsic to pulmonary vascular development.
Transgenic mouse studies wherein VEGF alleles have been
conditionally ablated in the lung epithelium results in a
phenotype exhibiting the near complete loss of the pul-
monary capillary network [5]. In humans, heterozygous loss
of VEGF leads to embryonic death andmarked abnormalities
of vascularisation [6]. VEGF is instrumental in generation of
the vasoactivemetabolites nitric oxide (NO) and prostacyclin
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(PGI2) via activation of endothelial nitric oxide synthase
and prostacyclin synthase, respectively. Both metabolites are
critical in the regulation of vascular tone [7, 8]. e TGF-𝛽𝛽
receptors and ligands are involved in lungmorphogenesis and
formation of the pulmonary circulatory systemwith the cyto-
plasmic mediators, the Smads, playing a role in pulmonary
artery endothelial cell (PAEC) proliferation, and migration
[9]. e angiopoietin family along with their receptor Tie-2
are important in endothelial cell migration and in the control
of vascular maintenance and remodelling. Defects in these
proteins results in extreme vascular abnormalities [10].
1.1. Haemodynamic and Structural Adaptation in Foetal and
Neonatal Pulmonary Circulation. e site of blood oxygena-
tion in the foetus is the placenta. At this stage of life the patent
foramen ovale (FO) and the patent ductus arteriosis (DA) are
open. e �ow of blood from the placenta is, thus, directed
away from the foetal lungs. Oxygenated blood is directed to
the chambers of the heart via the foramen ovale. Negligible
quantities of blood enter the lungs as the high resistance of
foetal pulmonary vasculature encourages diversion through
the ductus arteriosis.e resistance relates to themorphology
of the muscular arteries and arterioles, in which the smooth
muscle layer is thick and the lumen narrow [11–14]. Upon
birth, the lungs are employed in blood oxygenation. A fall in
pulmonary vascular resistance soon follows as a consequence
of pulmonary artery and arteriole dilatation concomitant
with an increase in systemic pressure.Upon systemic pressure
surpassing that of pulmonary vascular resistance the foramen
ovale shuts, soon followed by the contraction of the ductus
arteriosis [15, 16] (Figures 1(a) and 1(b)).
1.2. Haemodynamic and Structural Features of Postnatal
and Adult Circulation. e closure of the ductus arteriosis
and, subsequently, the foramen ovale generates a dramatic
increase of blood �ow through the lungs (Figure 1(c)).
During the �rst two or three weeks of life, signi�cant
structural changes to the muscular arteries and arterioles
occur. Considerable luminal widening with accompanying
medial thinning is exhibited. A more gradated decrease in
media width progresses over one and a half years until the
pulmonary vasculature reaches a steady adult state. Critical
to the signi�cant decrease in the postnatal circulation and,
indeed, themaintenance of the adult circulation is the change
in functional outcomes of signalling pathways comprising
key vasoactive elements. e adult pulmonary circulation
re�ects its structural features by being a low-pressure system
of between 7 and 15mmHgwith an average of approximately
9mmHg [17–20].
2. Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) represents a dra-
matic reversal of the physiological adult circulation to a
disease state bearing features of foetal high vascular resis-
tance. Whilst the disorder is uncommon with an incidence
calculated at 1-2 cases per million per year, it is progres-
sive and typi�ed by high morbidity and mortality. PAH is
clinically diagnosed when mean pulmonary artery pressure
is maintained at >25mmHg at rest or 30mmHg during
exercise with normal pulmonary capillary wedge pressure
and elevated pulmonary vascular resistance [21]. Diagnostic
protocols include patients having a Doppler echocardiogram
to determine right heart size and function, le ventricu-
lar diastolic and systolic function, and putative causes of
pulmonary hypertension [22]. Prior to a treatment course
being decided patients require right heart catheterization to
measure hemodynamic parameters, for example, pulmonary
arterial pressure and vascular resistance [23]. PAH aﬄicts
both adults and children but, in the main, occurs in the 3rd
to 4th decade of life. For reasons that are yet to be fully
explained the disease exhibits a sex bias aﬀecting twice as
many females thanmales [24]. A proportion of PAH patients,
approximately 10%, have a family history of disease which in
certain cases has been observed to be transmitted through
multiple generations [25]. Due to the advent of contemporary
therapies, patient life expectancy has been improved but
the disease remains incurable. In the absence of heart-lung
transplantation the disease, typically, remains fatal with death
occurring due to the strain imposed on the right side of the
heart. A signi�cantly lower number of male oﬀspring of PAH
aﬀected women has been noted, suggestive of selective male
foetal wastage. e condition appears to aﬀect all racial and
ethnic groups equivalently [24].
2.1. Classi�cation of Pulmonary Hypertension �PH�. As
de�ned by the 2008 World Health Organization symposium
onpulmonary hypertension, there exist 5major classes.ese
comprise: Group 1. PAH; Group 2. PH associated with le
heart disease; Group 3. PH associated with alveolar hypoxia
and/or other disorders of the respiratory system; Group 4.
romboembolic disease resulting in PH; Group 5. PH with
unclear multifactorial mechanisms. PAH itself is sub-divided
into 5 additional categories comprising idiopathic PAH
(IPAH), heritable PAH (HPAH), which identi�es patients
with multiple aﬀected family members and/or an identi�ed
germ-line mutation, PAH associated with known risk factors
for disease, PAH associated with additional diseases (APAH)
which may include HIV infection, systemic sclerosis, and
congenital heart disease. e �nal class is persistent pul-
monary hypertension of the newborn [26].
2.2. Functional Classes of Pulmonary Arterial Hypertension.
e World Health Organization, in addition to the clinical
classi�cation of PH, has developed a four tier classi�cation
system that segregates patients on the basis of disease severity
with Class I being the mildest and Class IV the most severe
form of disease. Patients falling within Class I comprise
individuals with PH that is not accompanied by constraints
on physical activity. Moreover, normal physical activity does
not result in dyspnoea, fatigue, syncope, or chest pain. Class
II patients have PH with mild limitation of physical activity
whereas Class III patients are severely impaired in the ability
to performphysically exerting tasks. Class IV patients present
with symptoms if any physical activity is performed; these
individuals are representative of end stage disease with clear
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F 1: Development of the circulatory system. Systemic and pulmonary circulation in the (a) foetus, (b) neonate, and (c) adult.e arrows
refer to the direction of blood �ow through the anatomical compartments, depicted by the labelled rectangular boxes.e oval shapes labelled
FO and DA refer to the foramen ovale and ductus arteriosus, respectively.
indications of heart failure. Additionally, shortness of breath
and general fatigue are evident in a resting state [27].
2.3. Histopathology of PAH. PAH is associated with the
development of vascular lesions and aberrant vascular re-
modelling. While a series of lesions are typically observed
in PAH, these can be present as heterogeneous populations
both within and between families suggesting that the initial
causal factor generating lesion types is the same. e arte-
rial circulation is predominantly impacted upon although
there is evidence of limited venous remodelling. A frequent
pathological observation in PAH is medial hypertrophy of
the muscular pulmonary arteries and muscularization of the
arterioles. Accompanying this is a duplication of the elastic
lamina and a characteristic thickening of the medial smooth
muscle (Figure 2). Aﬀected vessels are similar to foetal mus-
cular arteries albeit in an adult circulation system. A hallmark
pathological �nding in PAH is the plexiform lesion present
in approximately a third of patient lung tissue. Plexiform
lesions are typically associated with end-stage PAH but are
not emblematic of the disease as they are also observed with
other disorders arisingwith PH. Situated inmuscular arteries,
usually of an external diameter between 100–200 𝜇𝜇m, they
typically arise at the origin of pulmonary arterioles and
display aberrations of themedia and intimal lining.e lesion
is de�ned by the segmental destruction of themedial cell wall
layer.e lesion typically presents with a profusion of smooth
muscle cells, myo�broblasts, macrophages, and proliferating
endothelial cells. e upregulation of growth factors, such
as vascular endothelial growth factor (VEGF) and its recep-
tor, has been described in the endothelial cells within the
plexiform lesion [28–30]. e initiating factors and, indeed,
cell type responsible for the generation of plexiform lesions
remain a source of uncertainty. While debate continues as to
the source of lesional formation being smooth muscle cells
or endothelial cells an important observation has been the
report of endothelial cells within lesions being monoclonal,
suggestive of neoplastic expansion. Furthermore, plexiform
endothelial cells from idiopathic patients have been shown
to exhibit microsatellite instability in DNA repair genes, pro-
apoptotic genes and in theTGF-𝛽𝛽 gene, which is also a central
feature of cancer cells and is described as the “two hit” tumour
suppressor gene hypothesis [31]. Contrastingly, however,
cells obtained by microdissection of plexiform lesions from
lungs of HPAH subjects exhibited no evidence of similar
somatic mutations. ese data indicate that microsatellite
instability is unlikely to underpin both categories of PAH
[32].e arterial lumen, proximal to the lesion, is obstructed
by eccentric or concentric intimal �broelastosis. Distally, the
artery is markedly dilatated and thin-walled.
2.4. Disease Pathogenesis
2.4.1. Endothelial Cell Abnormalities. Imbalances in vasoac-
tive metabolites are a central feature of the vascular endothe-
lium of PAH patients. Vasocontrictive agents, for example,
thromboxane and endothelin-1, are found to be signi�cantly
upregulated in pulmonary arteries [33, 34]. By contrast, the
vasodilators prostacyclin, nitric oxide, and the nitric oxide
messenger cyclic guanosine monophosphate are present at
much reduced levels. rough unclear mechanisms, the
upstream catalysts of these proteins, prostacyclin synthase,
and nitric oxide synthase, respectively, are also greatly dimin-
ished in patient lung tissue [35, 36].
2.4.2. �n�ammation. In�ammation has long been recognised
as having a role in the development of PAH. Evidence of
heightened levels of in�ammatory cytokines in patient tissue
include tumour necrosis factor, IL-6, IL-1𝛽𝛽, and monocyte
chemoattractant protein 1 [37, 38]. Vascular lesions in PAH
patient lung display classic in�ammatory features which
include the presence of macrophages, monocytes, and T
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F 2: Cause and eﬀect in pulmonary arterial hypertension. Schematic representing the genetic and environmental factors involved in
the aetiology of PAH and the biochemical readouts associated with PAH presentation. BMPR2 haploinsuﬃciency remains the major genetic
contributant to disease pathogenesis.e central depiction of a section through a pulmonary artery shows the hallmark features at each stage
of PAH progression.
and B lymphocytes [39]. In�ammatory chemokines are also
found at elevated levels in PAH patients, in particular the
chemotactic protein FKN, RANTES, and chemokine ligand
5 [40].
2.4.3. Voltage-Gated Potassium Channels. Intracellular cal-
cium levels are regulated by voltage-gated potassium chan-
nels which act by regulating membrane potential and con-
trolling the release of calcium. Intracellular calcium is integral
in driving contraction of pulmonary artery smooth muscle
cells (PASMCs) and promoting hypertrophy. Calcium levels
in PAH smooth muscle cells have been shown to be elevated
likely as a direct consequence of the observed reduction
in transcript for potassium channels and low current in
patients by comparison to controls. e paucity of potassium
channels has been posited as a potential explanation for the
vasoconstriction and uncontrolled proliferation observed in
patients [41].
2.4.4. Serotonin and the Serotonin Transporter. IPAHpatients
exhibit elevated levels of serotonin (5-HT) which persist
post heart-lung transplantation. is �nding indicates a
causal role for 5-HT in the pathogenesis of PAH [42]. 5-HT,
stored primarily in the platelets, is a potent vasoconstricting
agent and mitogen which promotes smooth muscle cell
proliferation. e mitogenic eﬀects of 5-HT are mediated
by the serotonin transporter, 5-HTT [43]. Indeed, chemical
inhibition of 5-HTT results in a loss of 5-HT induced cell
proliferation. 5-HTT is expressed at high levels on PASMCs
and increased production of 5-HTT in PASMCs is capable of
triggering spontaneous PAH [44].
2.4.5. e Warburg Phenotype. Cancer cells display dysmor-
phicmitochondria and a glycolytic shi inmetabolismwhich
is believed to confer resistance to apoptosis [45].is cellular
phenomenon, known as the Warburg phenotype, has also
been observed in PASMCs and PAECs from human PAH
patients as well as in a rodent model of PAH [46]. is link
to a cancer phenotype appears to be associated with depleted
levels of the tumour suppressor gene and antioxidant enzyme
SOD2. SOD2 scavenges super-oxide, converting it to hydro-
gen peroxide in the mitochondria, a critical step in the
regulation of cell proliferation. Signi�cant downregulation of
SOD2 is observed in the pulmonary arteries and plexiform
lesions of PAH patients [47].
2.4.6. Extracellular Matrix. Mitogens in the extracellular
matrix (ECM) are released and tenascin-C upregulated due
to the abnormal degradation of the ECM by matrix met-
alloproteinases and elastases in patients. Tenascin-C has a
proproliferative eﬀect on smooth muscle cells as it enhances
the response to mitogenic agents. Studies have shown that
inhibition of these substances reduced vascular remodelling
and the severity of disease thereby indicating their impor-
tance in smooth muscle homestasis [48] (Figure 2).
3. Genetics and Genomics of PAH
Heritable PAH was �rst reported by Dresdale et al. in 1951
[49]. In families, the disease segregates in an autosomal
dominant manner and with markedly reduced penetrance
as indicated by the absence of overt disease symptoms in
BMPR2 haploinsufficiency
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multiple obligate carriers. Although all examined pedigrees
suggest that HPAH is a single gene disorder, the reduced
penetrance, sex bias, and disparity of age of disease onset both
within and between families serve to highlight complex traits
of inheritance [50]. Using microsatellite based genotyping
and standard linkage analysis in multiple families, a locus
for the causative gene was identi�ed by two independent
groups in 1997 [51, 52]. Nichols et al. employed 6 large
pedigrees for linkage studies and isolated a minimal linkage
interval of 25 cM with a maximum LOD score of 6.97 [52].
is large region was saturated with further markers of
high informativity and haplotype mapping was conducted
in several additional kindreds to re�ne the linkage peak by
the �ne mapping of recombination events amongst aﬀected
individuals. ese genetic analyses facilitated the re�nement
of the original 25 cM interval to a more tractable 4.8 cM
located on chromosome 2q33 [53]. Although typically a
late-onset autosomal dominant disease, microsatellite data
generated during the course of the linkage investigation did
not provide evidence of shared disease haplotypes in US and
UK populations that would be indicative of the presence of
founder mutations.
3.1. Transcript Mapping and Positional Cloning of the Gene
Underlying HPAH. To derive a clear appreciation of the
actual size of the interval and unambiguously position
polymorphic markers and, critically, expressed sequence
elements a physical map was created employing contigs
comprising YACs, BACs, and PACs.ese studies established
the interval as being 5.8Mb and harbouring within it 79
transcriptional units [53]. Characterized genes with likely
biological relevance to PAH were prioritized for analysis by
direct Sanger sequencing. Screening of a number of candidate
genes culminated in the identi�cation of independent het-
erozygous mutations, in numerous familial cases, of the gene
BMPR2 [54, 55]. BMPR2 encodes the transmembrane bone
morphogenetic receptor type II of the TGF-𝛽𝛽 superfamily
of signalling molecules. TGF-𝛽𝛽 molecules are indispensible
in a multitude of cellular activities which include prolifer-
ation, apoptosis, migration and diﬀerentiation [56]. Shortly
aer the identi�cation of BMPR2 defects in PAH families,
mutation analysis was extended to a cohort of patients with
sporadic onset of disease. All cases were rigorously screened
to ensure the absence of a family history, associated disease
and exposure to known risk factors. Initial investigations
revealed the presence of BMPR2mutations in 26% of patients
thereby expanding a role for this gene in the wider spectra
of PH. ereaer, several international studies have been
conducted on IPAH patients with mutation detection rates
ranging from 11–40% [57–60].
3.2. BMPR2 Structure and Function. BMPR2 is a relatively
large gene, consisting of 13 coding exons arrayed over 190 kb
of genomic DNA with a transcriptional start site at base
pair position −1148 relative to the initiation codon adenine.
It has an unusually long 3� UTR of approximately 11 kb
[61]. e transcript encodes a protein of 1038 amino acids
comprising an extracellular ligand binding domain (exons
2 and 3), a single pass transmembrane domain (exons 4
and 5), a highly conserved catalytic kinase domain (exons
6 to 11) and a cytoplasmic domain (exons 12 and 13) of
uncertain functional relevance. Of note, this cytoplasmic tail
is unique in length amongst other TGF-𝛽𝛽 receptors all of
which contain short intracellular tracts. Exon 12 is removed
by alternative splicing to render a naturally occurring shorter
receptor species which while, as is the case with the long
form, is ubiquitously expressed at the transcript level, the
protein product has not been extensively tested to determine
functionality [62].
e BMP signalling pathway is a highly regulated system
controlled on multiple layers and in a cell-speci�c manner
by a variety of mechanisms that include competitive ligand
binding, intracellular inhibition of receptor types and cell-
speci�c utilisation of diﬀerent receptor combinations to gen-
eratemyriad signalling outcomes. In its basic form, signalling
is initiated at the cell surface when extracellular ligand is
bound by a heterotetrameric complex comprising BMPR-
II and a type-I partner receptor which may be BMPR1A
or BMPR1B [63]. As an illustration of pathway speci�city,
in pulmonary endothelial cells, BMPR-II binds the type I
receptor ALK-1 which is predominantly expressed in the
endothelium in order to transduce signal in response to the
ligand BMP9 [64]. When brought together upon binding
ligand the constitutively kinase active BMPR-II transphos-
phorylates the GS domain of its type I partner thus activating
its catalytic domain. e type I receptor, next, contacts and
phosphorylates cytoplasmic eﬀector molecules, for example,
the receptor Smad proteins (R-Smads). BMP signalling is
diﬀerentiated from TGF-𝛽𝛽 pathways by the fact that each
activate a diﬀerent subset of R-Smads. In the case of the
BMPs, these are R-Smad1, 5, and 8 whereas the TGF-𝛽𝛽 recep-
tors phosphorylate Smads 2 and 3. Common to both systems
is Smad4 which binds the activated R-Smads and chaperones
them to the nucleus where, in combination with nuclear
cofactors they act, in complex, to regulate the transcription of
a target set of genes [63].More recently, it has become evident
that signalling routed through this pathway is far more
complex than previously thought. Several Smad independent
pathways have emerged from the characterization of BMPR-
II interacting proteins, for example, Tctex-1, LIMK-1, RACK-
1, tenascin-1, that regulate cellular processes which include
actin cytoskeletal dynamics and maintenance of the extra-
cellular matrix [65–68]. An important pathway regulated
by BMP signalling is that of p38MAPK [69]. Increasingly,
an understanding has grown of the mechanisms govern-
ing p38MAPK activation downstream of BMPR-II and,
indeed, Smad activation itself. Optimal signalling through
either downstream pathway appears to be dependent on
endocytosis of receptor complexes. Smad signalling requires
receptor internalization through clathrin-coated pits whereas
p38MAPK activation is reliant on receptor complexes being
endocytosed through a caveolae mediated route [70]. e
mode of receptor oligomerization is also considered vital in
determination of downstream pathway activation. Receptor
complexes may either be preassembled or induced by ligand;
in the former instance Smad signalling is the favoured
pathway whereas ligand recruitment of receptor complexes,
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the more commonmechanism, leads to alkaline phosphatase
activation via the p38MAPK pathway [71].
3.3. e BMPR2 Mutation Spectrum in HPAH. Mutations in
BMPR2 have been now reported in a multitude of ethnic
groups as a result of a systematic survey of exons, intron-exon
junctions, and, less frequently, noncoding regions including
the 5� and 3� UTR and putative promoter region. In the
main, point mutations in the gene have been examined using
Sanger sequencing and/or denaturing high-performance liq-
uid chromatography (DHPLC). Large scale gene rearrange-
ments have been screened for using multiplex ligation-
dependent probe ampli�cation (MLPA) technology in addi-
tion to conventional Southern blotting. ese independent
investigations, when combined, identify deleterious variation
in 70% of subjects with aﬀected relatives, with more likeli-
hood to be found when gene screening routinely advances
to analysis of intronic and regulatory regions. More unex-
pectedly, mutations of genes encoding BMPR-II and, indeed,
other members of the TGF-𝛽𝛽 superfamily have been detected
in PAH associated with other conditions or risk factors, for
example exposure to the appetite suppressant drugs fen�u-
ramine and dex-fen�uramine. e distribution and class of
mutation in hereditary and spontaneous disease is largely
indistinguishable. In both HPAH and IPAH, mutations are
arrayed across the gene, albeit at extremely low frequency
in exons 5 and 13, and comprise all categories including
missense, nonsense, frame-shi, splice-site, small deletions
and insertions, as well as larger gene rearrangements. To
date, over 300 independent mutations of BMPR2 have been
identi�ed [72]. In the main, the variant level of severity
has been inferred by con�rmation of segregation amongst
aﬀecteds and carriers in families, degree of evolutionary
conservation across species and occurrence in key functional
domains. However, representative examples of mutant alle-
les, impacting upon the major receptor domains, have been
taken forward by several research groups to in vitro functional
analysis of the eﬀect of identi�ed patient speci�c mutations
on downstream signalling pathways.
3.3.1. Haploinsuﬃciency Is the Primary Molecular Mechanism
of Disease. Mutations of BMPR2 likely to cause premature
truncation of the open reading frame constitute large gene
deletions and duplications (∼6%), splice-sitemutation (∼9%),
frame-shi (∼24%), and nonsense defects (∼29%).us, 70%
of all identi�ed mutations in HPAH would be predicted
to lead to aberrantly truncated mutant alleles [72, 73].
Truncating mutations have been detected across the gene but
spare the terminal exon 13. e eﬀect of truncating point
mutations on messenger RNA was assessed using patient
cell lines harbouring this class of mutation. e level of
the transcript under physiological conditions was estimated
by means of quantitative polymerase chain reaction (qPCR)
assays. As predicted, upon the addition of puromycin, a well
known inhibitor of the nonsense mediated decay (NMD)
pathway, transcript levels increased signi�cantly. ese data
indicate that the majority of mutations predicting premature
truncation are detected by the NMD surveillance machinery
and removed from the cell by degradation of the mutant
harbouring allele [74]. Taken together with the evidence of
large and whole gene deletions of BMPR2, these observations
�rmly establish haploinsuﬃciency as the central molecular
mechanism of disease in familial and sporadic forms of PAH
[75] (Figure 2). While the vast majority of truncating muta-
tions typically impact upon the coding region an interesting
exception is found in the form of a double substitution of
contiguous bases approximately 900 base pairs upstream of
the start site of translation. e GC < ATmutation was iden-
ti�ed in a large kindred and observed to segregate with the
disease phenotype. In silico analysis of the region of sequence
harbouring this variation suggested the introduction of a new
translational start site stronger than the wild-type which, if
employed, would lead to the incorporation of a premature
termination codon in exon 1 of the gene. As this event would
be predicted to produce a transcript susceptible to NMD,
allele-speci�c polymerase chain reactionwas employed to test
transcript levels from patient cell lines before and aer the
application of NMD inhibitors. e resultant data indicated
a consequent restoration of mutant message indicating that
NMD was being triggered. e detection of this novel muta-
tion serves to emphasise the likely presence of pathogenic
variation contained within noncoding sequence not typically
screened [61].
3.3.2. Amino Acid Substitution in HPAH. Missense muta-
tions underlying amino acid substitutions impact primarily
on areas of the receptor that are of pivotal catalytic and/or
structural importance. As such, this form of mutation has
been found to be largely restricted to those exons and, indeed,
residues that are pre-requisites for BMPR-II signalling activ-
ity. e majority of missense mutations have been identi�ed
in exons 2 and 3 encoding the extracellular domain, and
exons 6 to 11, encoding the kinase domain. Only a handful
of missense mutations have been identi�ed in exon 12,
responsible for the long cytoplasmic tail [72, 73].
3.3.3. Mutations of the BMPR-II Extracellular Domain. ree
dimensional structural studies reveal that the extracellular
domains of the TGF-𝛽𝛽 receptors, including BMPR-II, are
highly organised structures which bear resemblance to a class
of toxins known as the three �nger toxin family.is complex
fold is substantially dependent on the formation of �ve disul-
phide bridges themselves dependent on 10 cysteine residues
spread across the proximal exons. e importance of these
particular residues is indicated by the fact that they are invari-
ant in the majority of type II receptor species [76]. Of note,
amino acid substitutions within this domain predominantly
aﬀect the conserved cysteine residues, testimony to their
importance to receptor integrity. In vitro studies using tagged
constructs bearing cysteine mutations demonstrated that the
subcellular localisation of the encoded mutant proteins was
cytosolic by contrast to the plasma membrane positioning of
the wild-type receptor. ese results point to the likelihood
of normal membrane traﬃcking being compromised as a
consequence of protein misfolding leading to the trapping of
mutant receptors in the cytoplasm [77].
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3.3.4. Kinase Domain Defects in PAH. e kinase domain
of BMPR-II belongs, along with the other TGF-𝛽𝛽 recep-
tors, to the extensive and highly evolutionarily conserved
eukaryotic protein kinase (EUK) superfamily. Eukaryotic
kinases share structural and functional features as well as the
phosphate group transfermechanism. EUKs are composed of
12 subdomains each with speci�c functional characteristics
necessary to eﬀect the step-wise processes required for a
successful catalytic outcome. Broadly, the N-terminal end
of the receptor is responsible for adenosine triphosphate
binding while subdomains in the distal half are required
for substrate recognition of initiation of substrate phospho-
rylation. Within these subdomains are distinctive patterns
of conserved residues and, further, as revealed by X-ray
crystallography, invariant residues which are indispensible to
function [78].Missensemutations typically cluster within the
more highly conserved subdomains and conserved residues.
is is best illustrated by recurrent PAH-speci�c mutation
at position 491 in the amino acid chain. Within the kinase
domain this residue is critical to activity as it forms an
ion pair with a conserved glutamic acid at position 386.
By contrast, few variants, the majority of which may be
described as being of unknown signi�cance, arise in the
weakly conserved regions of the kinase domain, for example,
subdomain IV, which does not appear to play a major role
in kinase function or structure [72, 73]. All noncysteine
substitutions of the kinase domain are localised correctly
to the plasma membrane due to the structural integrity of
the receptor being preserved. Transient transfection of a
large series of mutant receptors harbouring kinase domain
defects indicate the loss of kinase function by their inability
to activate a Smad binding element upstream of a luciferase
reporter gene. In many cases the receptor was eﬀectively
kinase dead by comparison to wild-type controls. Intrigu-
ingly, it was also noted that transfection of both cysteine and
noncysteine receptors lowered luciferase readouts to below
base-line levels implying a dominant negative eﬀect on the
wild-type receptor. is was hypothesised as being a result
of sequestration of the wild-type partner by mutant receptors
into signalling defective complexes. However, it is oen the
case that assays of this nature do not accurately re�ect the in
vivo situation making over interpretation of the data unwise
[77, 79].
3.3.5.Mutations of the Cytoplasmic Terminus. Approximately
15% of the mutation load in PAH is con�ned to the cytoplas-
mic tail region with the vast majority of recorded mutations
in this domain truncating in nature [72, 73]. Of interest, the
small number of missense mutations observed in patients
are clearly distinct from the rest of the spectrum. ese
mutant receptors appear broadly analogous to wild-type in
the ability to translocate to the cell-surface and activate
luciferase reporters [77, 79]. To investigate the pathogenicity
of these variants, research streams turned to identifying
Smad-independent pathways, regulated by the cytoplasmic
domain, that were potentially of signi�cance in disease
precipitation and progression. To facilitate this objective, a
number of studies focussed on developing an understanding
of the role of the cytoplasmic tail in signalling by the
identi�cation of protein interacting partners. Amongst the
interacting proteins identi�ed were the cytoskeletal proteins
Tctex-1, a light chain of the macromolecular motor cytoplas-
mic dynein and LIMK-1, a regulator of actin polymerization.
Tctex-1 was discovered to be a kinase substrate of BMPR-
II; the presence of mutation in the cytoplasmic tail attenu-
ated this process. Mutations in this domain resulted in the
constitutive activation of LIMK-1 resulting in abnormalities
in actin dynamics [65, 66]. More recently, studies conducted
on a transgenic mouse harbouring a cytoplasmic domain
mutation (p.R899X), which due to massive overexpression of
the transgene acts in a dominant negative manner, demon-
strated augmented levels of Rho/Rho-kinase. Moreover, in
certain cell populations this resulted in increased production
of IL-6 which, when suppressed, ameliorated symptoms of
disease. No perturbation of the Smad signalling pathway
was observed suggesting that activation of Rho-kinase may
represent an additional disease pathway speci�cally related
to the cytoplasmic tail [80].
3.3.6. Pathway Dysregulation as a Result of BMPR-II Muta-
tion. e single pathway disrupted by all mutation irre-
spective of position is that of the proproliferative kinase
p38MAPK which is found to be upregulated by BMPR-
II mutation. p38MAPK has been linked, in vitro, to the
abnormal proliferation of PAH cells as this cellular defect can
be reversed in the presence of speci�c p38MAPK inhibitors
[77].
TGF-𝛽𝛽 signalling in normal PASMCs exerts an antipro-
liferative response. By contrast, BMPR-II defects in human
and experimental PAH appear to induce an upregulation in
TGF-𝛽𝛽 signalling in concert with a proproliferative eﬀect on
PASMCs. As examination of the canonical TGF-𝛽𝛽 pathway
did not uncover evidence of dysregulation, it was speculated
that Smad-independent signalling might play a role. Assess-
ment ofmutant cell lines with identi�ed BMPR2mutation led
to the discovery of an elevation in the expression and activity
of TGF-𝛽𝛽 activated kinase (TAK-1). As the downstream
substrates of TAK-1 include p38MAPK and ERK-1, it has
been posited that the increased pool of TAK-1, responding to
TGF-𝛽𝛽 stimulation, drives the uncontrolled proliferation of
mutant cells by activation of its substrates [81]. Davies et al.
drew a link between BMPR-II dysfunction and misdirected
NF-𝜅𝜅B signalling leading, in turn, to an increased production
of IL-6 and PASMC proliferation in response to abnormally
elevated TGF-𝛽𝛽 stimulation [82].
3.3.7. Atypical BMPR2 Mutations in APAH. e majority of
mutations observed in studies conducted on PAH associated
with other conditions and/or risk factors, primarily appetite
suppressant drugs, demonstrate a marked dissimilarity to
the HPAH mutation spectrum. In contrast to HPAH, over
90% of these variants are missense mutations which display
a diﬀerent pro�le to the amino acid substitutions in hered-
itary and spontaneous disease. Whereas cysteine residues
are predominantly mutated in HPAH, these residues are
spared in PAH associated with congenital heart disease
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and anorexigen intake. Moreover, many of the identi�ed
substitutions occur in regions of the receptor that make a
limited contribution to the functional and structural integrity
of the receptor, for example exon 5 of the gene. In vitro
reporter based studies aimed at determining the eﬀect of
a series of these reported APAH mutations on BMPR-II
signalling activity concluded that their ability to activate the
reporter gene was comparable to wild-type. Hence, inter-
pretation of the mechanisms by which these variants trigger
PAH is problematic. It is feasible that these alleles represent
low penetrance risk factors that require additional environ-
mental insults and genetic modi�ers to precipitate disease
[72, 73].
3.3.8. Recurrent BMPR2 Mutations in HPAH. Mutations
observed on multiple occasions in unrelated cases accounts
for approximately 40% of observed variation in HPAH and
are comprised of at least 25 independent defects. While
large-scale systematic studies have not been performed to
determine whether these mutations arise from common
founder haplotypes, those mutations which have been anal-
ysed (c.994C>T (p.R332X), c.2579delT (p.N861fsX10) and
c.2695C>T (p.R899X)) by microsatellite marker haplotyping
clearly con�rm that in each case the mutation was harboured
in a distinct haplotype with no evidence of marker sharing
between patients [72, 73]. ese results support the hypoth-
esis of a recurrent mutation process in favour of the presence
of ancestral mutations ascertained in multiple individuals.
Moreover, the majority of the observed recurrent mutations
occur at CpG islands and, thus, likely arise as a result
of spontaneous deamination of methylated cytosines with
subsequent conversion to thymidine, a relatively common
mutational mechanism. Recurrent frameshi mutations as a
result of small insertions and deletions are typically found in
regions of low sequence complexity, potentially implicating
replication slippage as a cause for mutation at those posi-
tions. Investigation of isolated populations, notably that of
Finland, also failed to uncover evidence of foundermutations
indicating that if it does exist it is most likely uncommon
[83].
3.3.9. Genotype-Phenotype Correlations. Analyses of a rela-
tionship between mutation class and position with broad
disease parameters including age of onset, hemodynamic
function in patients, and survival failed to yield data indica-
tive of a meaningful correlation. More recently, research
into putative correlations has endeavoured to interrogate
more subtle aspects of phenotype. Elliott et al. attempted to
assess the relationship between BMPR2 sequence variation
and vasoreactivity, an important clinical consideration in the
treatment of patients using vasodilators such as prostacyclin
analogues. A total of 67 familial and idiopathic patients were
investigated for BMPR2 nonsynonymous variation, of which
27 patients proved positive for variation with 22 harbouring
bona �de pathogenicmutations. Vasoreactivity was evaluated
between the sets of patients with and without variation using
stringent clinical criteria. None of the mutation carriers were
found to be vasoreactive by contrast to 35% of patients with
no form of variation. ese results are a compelling indica-
tion of a correlation between defective BMPR-II signalling
and vascular tone and responsiveness [84].
In a Chinese study comprising 305 individuals, the
presence of BMPR2 mutations was noted to be associated
with higher risk of mortality once adjusted for age and
gender. e eﬀect was most prominent in the male group
but did not reach statistical signi�cance in females which the
authors attributed to the more complex disease aetiology in
women [85].
In seeking to explore the reasons behind the remark-
ably low penetrance in BMPR2 mutation carriers Cogan
et al. examined the role played by alternatively spliced
isoforms of the gene. A comparative analysis was con-
ducted between lymphocytes from 47 aﬀected mutation
carriers versus 35 unaﬀected mutation carriers. Patients
were determined to have a signi�cantly higher ratio of
the allele lacking exon 12 to the full-length transcript by
comparison to carriers. Scrutiny of exon 12 revealed the
presence of an exonic splice enhancer capable of binding
serine/arginine-rich splicing factor 2 (SRSF2) which pro-
motes exon inclusion. SRSF2 levels were found to be lower in
patients than carriers and, theoretically would be anticipated
to result in an elevation of levels of the shorter isoform
[86].
3.4. Locus Heterogeneity in PAH
3.4.1. ALK and Endoglin. PAH, infrequently, may copre-
sent with the vascular disorder hereditary haemorrhagic
telangiectasia (HHT) wherein patients have PAH clinically
and histopathologically identical to the hereditary form of
disease, although PAH can also develop as a direct conse-
quence of the pathophysiology of HHT. HHT, or Rendu-
Osler-Weber syndrome, is an autosomal dominant disease
with an incidence of approximately 1/10,000 in Europe.
HHT is characterised by abnormal vascular development
and a range of distinctive clinical complications. An early,
common symptom is epistaxes (nosebleeds), observed in up
to 90% of aﬀected individuals. Other clinical manifestations
may include telangiectases, red to violet lesions that develop
on digits; the facial, nasal, and buccal mucosa; and the
gastrointestinal (GI) tract. Haemorrhage from the GI bed,
noted in 20–40% of patients, is progressive and can result in
chronic anaemia [87].
Arteriovenous malformations (AVMs) engineer a direct
communication between the arterial and venous systems that
bypasses the capillary bed. AVMs have been detected in the
pulmonary circulation in 25% of HHT cases; the hepatic
circulation in 8–16% of patients and the cerebral circulation
in 15% of the aﬀected population. AVMs are considered to
be a major contributant to morbidity and mortality in HHT
patients [87].
Although the primary pathophysiological defect in HHT
has yet to be determined, genetic linkage studies have
revealed molecular heterogeneity in HHT and the identity
of two loci. e disease genes at chromosome 9q34 and
12q13 have been identi�ed as encoding the TGF-𝛽𝛽 pathway
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receptors endoglin and ALK1, respectively [88, 89]. Non-
linkage to chromosome 9 and 12, in two HHT pedigrees, has
suggested the likelihood of a third, as yet unidenti�ed, locus
[90]. Endoglin is a 14 exon gene, expressed at high levels on
human vascular endothelial cells. Disparate mutations have
been recorded in endoglin and appear to correlate to a severe
clinical phenotype, with a high incidence of pulmonary
AVMs (PAVMs) [91].
ALK1 is organised into 10 exons with the �rst translated
methionine within exon 2. Families, with segregating ALK1
mutations, tend to exhibit late-onset and milder disease
manifestation. PAVMs have never been reported in patients
bearing mutations in this gene. e molecular basis of
dominance, in both endoglin and ALK1, is widely accepted
as being that of haploinsuﬃciency [92].
ALK-1 and endoglin are type I and type III receptors
respectively operating within the TGF-𝛽𝛽 pathway. is bio-
logical link with BMPR-II suggested a common molecular
aetiology in patients with PAH-HHT. Five pedigrees in which
both diseases were cosegregatingwere analysed formutations
in the three genes encoding these receptors. Screening of
the coding regions and intron/exon boundaries revealed the
presence of two truncating mutations and three missense
mutations inALK1, thereby identifying a second gene predis-
posing to the development of pulmonary hypertension [93].
Since the original report of ALK1 as an underlying factor
in PAH, several groups have analysed additional cohorts
and thereby built on the mutation spectrum of the gene.
ese studies now reveal that 20% of all known ALK1
mutations lead to the onset of PAH and, of these, 81% are
distinct to defects causingHHTalone.Of the identi�edmuta-
tions, amino acid substitutions constitute the predominant
class and aﬀect functionally key domains of the receptor,
in particular the kinase domain and NANDOR box [94].
More recently, evidence has emerged of ALK1 mutations
causing PAH in the absence of HHT. However, it must
be noted that these subjects, in the main, have early-onset
or childhood PAH thus retaining the possibility that HHT
could develop at a later stage [95]. Endoglin mutation may
also represent a rare cause of PAH-HHT with four defects
detected in patients thus far. All endoglin mutations would
be expected to lead to premature truncation of the transcript
[73].
3.4.2. SMADs 1, 4, and 9. ediscovery ofmutations in three
members of the TGF-𝛽𝛽 family leading to susceptibility to
PAH emphasizes the role played by this signalling pathway in
the maintenance of the pulmonary architecture. A number
of recent studies have sought to expand on these �ndings
by examining members of the downstream pathway for
deleterious variation in patients in whom the known risk
factors have been eliminated. Bymeans of a direct sequencing
approach in a limited cohort of 23 Japanese cases, Shintani
et al. isolated a mutation in the BMP-speci�c receptor Smad
gene SMAD9 (p.C202X) predicting the incorporation of a
premature truncation codon [96]. In the largest candidate
gene study conducted in PAH a total of 324 idiopathic and
associated PAH patients, previously excluded for mutations
in BMPR2, ALK1, and endoglin, were screened for SMAD1,
-4, -5, and -9 by Sanger sequencing. is analysis resulted
in the detection of 4 variants in the IPAH panel consisting
of 198 cases, each of which was absent in a panel of 1000
controls and 60 fully sequenced exomes. ese variants
in SMAD1 (p.V3A), SMAD4 (p.N13S; c.1448-6T>C), and
SMAD9 (p.K43�) may de�ne an additional 2.2% of the
IPAH population with a genetic background to disease.
However, whilst signi�cant, it was found that the impact of
these variants on functional outcomes was less extreme than
classical BMPR2 mutation. erefore, they fall into the cat-
egory of variants of unknown signi�cance that, potentially,
require other environmental and genetic factors to prove
pathogenic. Alternatively, these defects may impact upon
Smad-independent pathways, the investigation of which was
not within the scope of this study [97]. Of interest, SMAD9
had previously been associated with disease precipitation and
progression due to the onset of manifest PAH in a Smad9
knock-out mouse model. e SMAD9 defects in the human
studies are thus especially convincing in the light of the
mouse model exhibiting clinical and histopathological fea-
tures of PAH near identical to that observed in patients [98].
Two amino acid substitutions of the type I receptor BMPR1B
(p.S160N and p.F392L) were recently identi�ed upon the
screening of a panel of 43 IPAH patients. In vitro and reporter
assays indicated that the downstream eﬀect of these variants
was to induce increased production of Smad9 associated with
or responsible for an increase in transcriptional activity sug-
gestive of a gain-of-function mechanism. As both the human
studies, on the basis of functional analyses, when combined
with heterozygous loss of Smad9 in the mouse, suggested
haploinsuﬃciency as the molecular mechanism for disease,
the conclusions drawn by Chida et al. appear to contradict
the preceding three reports. Further functional testing is
required to fully elucidate the pathogenicity of these variants
[99].
3.4.3. Caveolin-1. Homozygous Caveolin-1 (Cav1) knock-
out mice develop moderate PAH indicating a role for this
gene in the aetiology of disease [100]. Next-generation
sequencing technologies, in particular full exome sequenc-
ing, have transformed the �eld of disease gene identi�cation
by facilitating the rapid analysis of the entire exome in patient
samples. By taking advantage of this methodology Austin
et al. successfully identi�ed a second causal gene in familial
PAH, namely the human orthologue of Cav1. e analysis of
4members of amulti-generational family led to the detection
of a truncating mutation in CAV1 (c.474delA), a �nding
which was consolidated by the subsequent demonstration of
mutation segregation amongst the other aﬀected members
of the family. e CAV1 variant was observed in unaﬀected
members of this family and this was interpreted as, poten-
tially, being due to incomplete penetrance in a similar vein
to mutations of BMPR2. Analysis of a replication cohort
by Sanger sequencing led to the identi�cation of a second
premature truncation (c.473delC) in a single IPAH case
lending plausibility to the likelihood of the gene representing
a rare inherited risk factor in familial PAH [101].
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3.5. Modifying Factors Conferring Risk of Disease. Although
PAH is an oligogenic disease, family studies demonstrate
clinical features reminiscent of a complex disorder, for
example, gender bias and reduced penetrance.is concept is
lent strength by the existence of several pairs of monozygotic
twins discordant for disease [73]. ese observations suggest
the existence of genetic modi�er genes either promoting or
protecting against disease.is hypothesis has been subject to
much investigation in the form of examination of annotated
variation in candidate genes believed to be involved in
disease pathogenesis. Amongst others, these include the
genes encoding the angiotensin converting enzyme (ACE),
the serotonin transporter (at least four independent investi-
gations), endoglin, prostaglandin synthase, and the voltage
gated potassium channel subunit Kv1.5 [102–109]. e con-
founding factor aﬀecting all these studies is the small sample
size employed in each case which would not have the statisti-
cal power to detect modifying variation of small or moderate
eﬀect size. Moreover, validation of initial observations by
means of a replication study in an independent cohort has
not been attempted. Con�rmation by replication studies is
now acknowledged as being an essential component of any
case control association analysis. In its absence these studies
remain incomplete and conclusions drawn, whilst tantalising,
have to be treated with some caution. In recent times, the
development and wide-spread utilisation of the HapMap
resource has revolutionised genome-wide association studies
(GWAS). is form of analysis obviates the ineﬃcient inter-
rogation of limited variable loci in a few genes and, combined
with the advances in genotyping technology, allows for a
rapid examination of several hundred thousand independent
loci in large sample sets. e relative lack of success of
the candidate gene approach makes a GWAS a much more
appealing study design option and one with potential to yield
important new insights. Sample size remains an important
consideration and due to the low incidence and prevalence of
PAH, it is clear global cooperation is required to obtain case
groups in excess of 1000 samples.
3.6. Animal Models of PH. e Fawn-Hooded rat (FHR)
is a spontaneous model of pulmonary hypertension when
exposed tomildly hypoxic conditions.While the trait appears
to be hereditary there are phenotypic distinctions between
PH in this animal and the human condition [110].
Five arti�cially generated mouse models harbouring
BMPR2mutation have been reported and routinely employed
in the study of the consequences of BMPR2 disruption
on the molecular and phenotypic level. e value of these
animal models is twofold. Even in the absence of manifest
disease symptoms murine models carrying domain speci�c
BMPR2 defects provide an invaluable and sustainable source
of mutant cell lines that may be employed for interrogation
of the BMP pathway in the disease cell and, further, can be
characterized on the phenotypic level to gain an insight into
the impact of mutation on cellular function. e ultimate
goal is that these models go on to recapitulate the disease
phenotype, in full or in part, to support the development
of research targeted at providing therapeutic options for
patients. Two mouse models were generated by utilisation of
homologous recombination knock-outmethodologies aimed
at the removal of exon 2 and exons 4 and 5, respectively.
In both instances the mutation proved to be homozygous
lethal with the mutant animals dying in utero. Whilst
both animal models displayed numerous developmental
anomalies, cardiac defects particularly of the out�ow tract
were especially notable in the exon 2 knock-out mouse.
In the heterozygous state, these mice were healthy and
did not develop measureable features of disease. However,
by comparison to wild-type mice, the mutant carriers dis-
played a signi�cantly higher susceptibility to disease when
exposed to environmental risk factors, for example exposure
to hypoxia and the in�ammatory agent 5-lipooxygenase
[111, 112]. A widely used model is a mouse harbouring a
point mutation (p.R899X) in exon 12 of the BMPR2 gene
generated by a knock-in strategy. Analogous to the knock-
out mice, mutant animals are nonviable in the homozy-
gous condition and asymptomatic in the heterozygous state
[113].
Transgenic mouse models are produced through overex-
pression of a mutant allele introduced as a cDNA construct.
As such, they less accurately re�ect the genetic architecture
of the human mutant carrier. Two transgenic mouse models
have been developed to overexpress the point mutations
c.504insT and c.2695C>T, driven by the smooth muscle
speci�c promoter SM22, both of which predict incorporation
of a premature termination codon [114, 115]. In nature,
these mutations would be expected to be lost via the NMD
pathway. However, as the NMD process is contingent on
the presence of intronic regions, these mutant alleles are
spared and expressed in protein form. e presence in
the cell of multiple copies of these mutant alleles led to
the spontaneous development of aspects of disease. Mice
displayed increased pulmonary artery pressure and vessel
muscularization. It may be hypothesised that these disease
alleles behave in a dominant-negative fashion by acting as a
trap for wild type receptors thereby diminishing the available
pool of receptors capable of forming active complexes.
e precipitation of overt pulmonary hypertension in the
transgenic mice lends support for a threshold model of
disease. While BMPR2 haploinsuﬃciency is a major factor in
predisposition to disease, it is not in itself enough to trigger
disease in the majority of mutation carriers. Additional
factors would appear to be required for disease to manifest
and, foremost among these, is the inexplicable loss of wild
type receptor in the cells of patients with severe disease.
Together with the observations made on the transgenic
mouse models, it is likely that a progressive reduction of
BMPR-II levels is what is required for a disease state to occur
[116].
4. Treatment Options in PAH
Treatment for PAH, while much improved in recent times,
remains ameliorative and, in general, PAH continues to be
a disease distinguished by high morbidity and mortality. All
patients are required to undergo a test for vasoreactivity,
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typically with adenosine or epoprostenol delivered intra-
venously and/or inhaled nitric oxide. e patient’s response
is considered positive when the mean pulmonary artery
pressure is lowered by 10mmHg and remains less than
40mmHg with no alteration in cardiac output and systemic
pressure. Patients exhibiting a positive response are usually
�rst administered calciumchannel blocker treatments� unfor-
tunately the vast majority of patients are nonresponsive and
require alternative medical interventions. Calcium channel
blockers including diltiazem and nifedipine are delivered at
low initial doses and gradually augmented to the maximum
level tolerated. Aer time, the eﬃcacy of this form of
treatment decreases and other options need to be explored
[117].
4.1. Prostacyclin Analogues. e study of cellular pathways
disrupted in the progression of PAH has pinpointed three
cellular systems that have proven to be amenable to thera-
peutic intervention. e prostacyclin metabolic pathway is
known to be dysregulated in PAH as indicated by reduced
expression of prostacyclin synthase in the pulmonary arteries
and of prostacyclin metabolites in the urine. Prostacyclin is
a multifunctional prostanoid that functions as a powerful
vasodilatory agent, an inhibitor of proliferation and platelet
aggregation, all hallmark features of the PAH pulmonary
circulation [118]. ere are three prostacyclin analogues
commonly used in patient care, namely epoprostenol, tre-
prostinil, and iloprost. Epoprostenol is continuously admin-
istered intravenously at a starting dose of 2 ng/kg/min with
an optimal level between 25–40 ng/kg/min [23]. Several
substantial studies testify to the eﬃcacy of the treatment in
alleviating haemodynamic abnormalities in patients when
compared against older, conventional therapies. Improve-
ments were noted in mean arterial pressure, exercise capacity
as measured by a 6minute walk test, and pulmonary vascular
resistance. Sitbon et al. conducted a longitudinal study of
178 patients with severe PAH over a �ve year period and
noted survival rates of 85%, 70%, 63%, and 55% over 1, 2,
3, and 5 years [119]. Epoprostenol has been associated with
side eﬀects of varying severity that may range from diarrhoea
to thrombosis [120]. Treprostinil is also associated with
signi�cant improvements in hemodynamic and symptomatic
outcomes in patients when infused subcutaneously. As a
monotherapy, treprostinil delivers better survival rates than
epoprostenol with survival at 88% at one year and 70% at
four years by comparison to 69% and 38% [121]. While
the adverse eﬀects of this treatment are broadly similar to
intravenous injection of epoprostenol, when treprostinil is
used intravenously it has potential to lead to a heightened
risk of gram negative blood stream infections as well as life
threatening catheter infections [122]. Unlike epoprostenol
and treprostinil, iloprost is a stable prostacyclin analogue
that remains eﬀective for a longer period of time. It also
provides the considerable advantage of obviating catheter
related complications as it can be inhaled in aerosolized form.
A largemulti-centre trial, comprising 207 patientswith severe
PAH (Class III and IV), demonstrated that iloprost therapy
resulted in an improvement of at least one functional class
[123]. Deleterious eﬀects of iloprost usage are generally mild
by comparison to the other commonly employed prostacyclin
analogues.
4.2. Endothelin-1 Blocking Agents. Endothelin-1 has long
been considered to be involved in the aetiology of PAH. It is
signi�cantly upregulated in the circulation of PAH patients
leading to the development of agents capable of blocking
its eﬀects, most prominently bosentan, sitaxsentan, and
ambrisentan. Unusually, bosentan is an endothelin antago-
nist that is capable of blocking both ETA and ETB receptors.
Kaplan-Meir survival curves indicated that survival rates
of patients treated with bosentan were 96% and 89% in
years 1 and 2, respectively [124]. ese estimates compared
favourably with patients undergoing epoprostenol. Bosentan
improves symptoms, haemodynamics, and exercise capacity
but can lead to dangerous side eﬀects which include liver
problems and hypotension. Male subjects may be at risk
of infertility and testicular atrophy [125]. Ambrisentan is
a speci�c ETA receptor antagonist that has been shown
by place controlled trials of randomized patients to eﬀect
sustained improvements in pulmonary haemodynamics and
exercise capacity. While possible testicular atrophy remains
a signi�cant side eﬀect, unlike bosentan, the risk of liver
damage is low [126].
4.3. Combined erapy. When monotherapy begins to fail
to improve symptoms and quality of life in patients a
combinatorial strategy is next employed. ese, typically,
consist of the dual administration of a prostacyclin analogue
with an endothelial antagonist. Whilst anecdotal evidence
does point to improvements in functional readouts, reduced
toxicity, and eﬃcacy of treatment, thus far only a few
clinical trials have been run to validate these observations. A
placebo controlled study of 405 PAH patients revealed that
a combination of bosentan with tadala�l, more known for
its usage in treating erectile dysfunction, drove a quanti�able
improvement in exercise capacity allied to retardation of
clinical worsening [127]. In an analysis of 267 PAH patients,
compared to patients treated with placebo while on intra-
venous epoprostenol, those given sildena�l showed signi�-
cant improvements in cardiac outputs and mean pulmonary
arterial pressure [128].
4.4. erapy for End-Stage Disease. e majority of patients
even when bene�ting from the highest levels of contem-
porary PAH therapy will progressively worsen to a criti-
cal life-threatening stage. At this time invasive procedures,
oen atrial septostomy followed by lung transplantation are
typically the last remaining options. An atrial septostomy
is a procedure designed to introduce a shunt, or conduit,
between the right and le atria. is adaptation reduces
the blood volume in the right side of the heart and, as
a consequence, reduces the work-load in pumping blood
to the lungs and improves the ventricular function of the
heart. While this procedure provides a measure of clinical
stability, it is considered only a precursor to eventual lung
transplantation. Lung transplantation, which may be single
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lung transplantation, double lung transplantation, or heart
and lung transplantation, is considered the last therapeutic
resort for PAH patients. Following transplantation, patient
survival rates have been reported as 66%, 57%, 47%, and
27% at years 1, 3, 5, and 10, respectively [129]. e type
of lung transplantation chosen for recipient patients varies
internationally from centre to centre.
4.5. Current Approaches to erapy. Recent data released by
the Registry to Evaluate Early and Long-term Pulmonary
Arterial Hypertension, a longitudinal study of patients from
North America, and the French Network on Pulmonary
Hypertension, underlines the fact that even with recent
improvements in therapeutic protocols, survival �gures over
three years is still unacceptably modest [130, 131]. Research
into PAHhas noticeably attempted to address this continuing
problem by seeking to translate pathway based studies to
therapeutic options. While palliative care has been undoubt-
edly important in transforming the patient’s quality of life,
there is increasingly a sense of urgency to employ the growing
understanding of defects in the BMP pathway to create
directed therapy protocols with the potential to permanently
halt or reverse the progression of this disease. To do so,
such treatments would be expected to demonstrably remove
clinical features of PAH, for example vascular lesions by
reverse vascular modelling, and promote the restoration of
homeostatic balance between vasoconstrictive and vasodila-
tory agents.
4.6. Gene erapy. e confounding factors present in the
application of gene therapy to human disease are numer-
ous and have stalled the application of this technology to
PAH until recently. Complications inherent in gene-based
therapies include insertional mutagenesis as well as practical
limitations, for example, vector design and delivery, the
short duration a bene�cial outcome will last and, perhaps,
most pertinently in PAH the correct cellular target. Reynolds
et al. sought to overcome some of these impediments in
a recent study on gene delivery in two experimental rat
models of PAH: PAH induced by chronic hypoxia and
monocrotaline (MCT)-induced PH. Both rat populations
recapitulated the hallmark features of disease, namely raised
pulmonary vascular pressure and evidence of vascular mod-
elling. Although neither model harboured BMPR2mutation,
both had diminished levels of the encoded protein, an as
yet unexplained phenomena also observed in PAH patients
negative for mutations of the gene. e authors speci�cally
targeted the pulmonary endothelium with a BMPR2 ade-
noviral gene delivery vehicle by the linkage of a bispeci�c
antibody to the angiotensin-converting enzyme. BMPR-II
expression was detected in and con�ned to the pulmonary
arterioles and alveolar capillaries. Receptor expression was
absent in the cardiac sections tested indicating successful and
speci�c delivery to the lung. Introducing the vector to the
endothelial layer of pulmonary arteries resulted in a marked
improvement in pulmonary haemodynamics includingmean
pulmonary arterial pressure and right ventricular systolic
pressure. Of interest, these changes while positive, were less
impressive in themonocrotalinemodel and did not reach sta-
tistical signi�cance. In both models there was clear evidence
of a reduction in abnormal vascular remodelling most likely
due to a concurrent decrease in the uncontrolled expansion
of the endothelial and smooth muscle layers. Recent studies
have drawn a clear link between the elevation of TGF-𝛽𝛽
expression and activity in the lung tissue of PAH patients
with disease pathogenesis. In the case of the experimental rat
models, this disease trait was identi�ed in the MCT treated
mouse but was absent in the hypoxia induced model, in itself
evidence of the fact that whilst of utility animal models do
not fully mirror the human disease state. Nonetheless, the
depression of TGF-𝛽𝛽 activity is amuch sought aer therapeu-
tic goal and the upregulation of BMPR-II signalling activity
via adenoviral delivery was found to quench the exuberant
TGF-𝛽𝛽 response in the MCT rat model. In follow-up studies
conducted on human pulmonary microvascular endothelial
cells in vitro, this study noted that the restoration of BMPR-
II levels and, by extension, rescue of BMP signalling blocked
TGF-𝛽𝛽 induced endothelial-mesenchymal transition. is
is certainly an important observation but its mechanistic
signi�cance in the aetiology of PAH remains to be fully inves-
tigated. e primary impact of this particular study is that
both rat models, with markedly diﬀerent initiating factors
precipitating disease and substantially distinct phenotypic
responses to environmental insults, nonetheless responded
to BMPR-II levels being heightened in the correct cell type.
ese data suggest that the common denominator between
diﬀerent categories of PAH is the level of BMPR-II, likely
in the endothelial layer, dropping below a threshold level
whereupon the disease state overtly manifests. On a therapy
level, this gene delivery option if applicable to humans may
bene�t a wide spectrum of PH suﬀerers including those
without BMPR2mutation [132].
As described previously, prostaglandin enhancement is a
vital form of treatment in PAH on account of the disruption
of this pathway in the progression of the disease. Yet, this
form of treatment loses eﬃcacy over time and, moreover,
is associated with several potential complications. Patient
quality of life ismuch impairedwhen prostacyclin is delivered
by use of integrated catheters administering continuous
intravenous medication and, additionally, the risk of catheter
related infection is signi�cant. PAH was induced in the
mouse by prolonged exposure to hypoxic conditions and
these animals were employed in a study of the potential
feasibility of Prostaglandin I2 Synthase (hPGIS) gene delivery
in the attenuation and/or reversal of disease symptoms.
Moreover, Kataoka et al. investigated the eﬃciency and eﬀect
of an adeno-associated virus (AAV) vector in gene delivery
and, further, extended these investigations to diﬀerent AAV
serotypes. Two AAV vectors, type I and type II carrying the
hPGIS transcript, were injected into the thigh skeletal tissue
of hypoxia induced (10% O2) PAH mice which had been
exposed to the risk condition for 8 weeks. Both treatments
resulted in a decrease of right ventricular systolic pressure,
the ratio of right ventricular weight to body weight, and
the ratio of RV weight to le ventricular plus septal weight,
measures that all reached statistical signi�cance. Addition-
ally, the treatment resulted in a reversal of thickening of
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the medial wall of pulmonary arterioles. In conclusion, both
vector systems were equally eﬀective in halting and, indeed,
reversing aspects of the pathogenic PAH phenotype [133].
Yet, it is equally apparent that major obstacles need
be overcome. It is unclear, given the present technological
constraints, whether this form of treatment is indeed the
Holy Grail for suﬀerers of PAH. e questions that need to
be explicated consist of, but are not con�ned to, whether
a gene delivery system that can maintain extended periods
of expression is an achievable aim in the foreseeable future.
In addition, can a swi change in the cellular environment
by, for example, restoring BMPR-II levels, eﬀect a long-
term alteration in the framework of the cells comprising the
pulmonary circulation? Most importantly, the basic science
aﬀected by treatment such as this needs to be fully explored.
Are other non-disease systems impacted by treatment and in
what way?ese andmanymore considerations remain to be
interrogated.
5. Future Directions
ere is still genetic variation to be uncovered in all forms
of PAH. is will be greatly aided by the advent of next-
generation sequencing and genotyping systems which will
facilitate the discovery of rare and common variation under-
lying disease. Signi�cant eﬀort needs to be applied in fully
elucidating the epidemiology of this condition, in particular
to aid genetic counselling of patients. Treatment options, in
light of the molecular breakthroughs achieved thus far, must
aim higher and execute treatments that become more than
simply palliative but, instead, curative.
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